COFCO Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
COFCO Biotechnology has a total shareholder equity of CN¥10.9B and total debt of CN¥3.9B, which brings its debt-to-equity ratio to 35.4%. Its total assets and total liabilities are CN¥17.2B and CN¥6.3B respectively.
Key information
35.4%
Debt to equity ratio
CN¥3.86b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.67b |
| Equity | CN¥10.90b |
| Total liabilities | CN¥6.28b |
| Total assets | CN¥17.18b |
Recent financial health updates
COFCO Biotechnology (SZSE:000930) Is Making Moderate Use Of Debt
Jan 07
We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt
Sep 30COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
Jun 03Recent updates
COFCO Biotechnology (SZSE:000930) Is Making Moderate Use Of Debt
Jan 07COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement
Oct 14We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt
Sep 30COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough
Jul 17COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
Jun 03Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)
Apr 17COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking
Mar 07Financial Position Analysis
Short Term Liabilities: 000930's short term assets (CN¥6.8B) exceed its short term liabilities (CN¥5.7B).
Long Term Liabilities: 000930's short term assets (CN¥6.8B) exceed its long term liabilities (CN¥618.2M).
Debt to Equity History and Analysis
Debt Level: 000930's net debt to equity ratio (20.1%) is considered satisfactory.
Reducing Debt: 000930's debt to equity ratio has reduced from 49.6% to 35.4% over the past 5 years.
Debt Coverage: 000930's debt is well covered by operating cash flow (20.5%).
Interest Coverage: Insufficient data to determine if 000930's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/20 14:57 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
COFCO Biotechnology Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Huang | China Merchants Securities Co. Ltd. |
| Xia Sheng | Citic Securities Co., Ltd. |
| Jian Zhou | Guoyuan Securities Co., Ltd. |